8 July: Biogen files for FDA license for aducanumab
On 8 July, the biotechnology company Biogen completed the submission of a biologics license application to the US Food and Drug Administration (FDA) for aducanumab as a treatment for Alzheimer’s disease (AD). Biogen requested a priority, six-month review, which has since been granted by the FDA, meaning a response will be given by 7 March 2021.
Read more »
|
28 July: Impact of COVID-19 on dementia research must be addressed
On 28 July 2020, following engagement with its national members, research funders and industry partners, Alzheimer Europe issued a position statement highlighting the pressure on dementia research as a result of COVID-19. To address these issues, the position statement sets out a number of recommendations aimed at research funders and research institutions.
Read more »
|
|
|
|
|